Poseida Therapeutics
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
Launch date
Employees
Market cap
$298m
Enterprise valuation
$144m (Public information from Sep 2024)
Share price
$3.61 PSTX
San Diego California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | <1m | 130m | 64.7m | 86.6m | 43.3m | 22.0m |
% growth | - | - | 417635 % | (50 %) | 34 % | (50 %) | (49 %) |
EBITDA | (<1m) | (<1m) | (57.1m) | (109m) | - | - | - |
% EBITDA margin | - | (389 %) | (44 %) | (169 %) | - | - | - |
Profit | (<1m) | (<1m) | (64.0m) | (123m) | (146m) | (235m) | (288m) |
% profit margin | - | (400 %) | (49 %) | (191 %) | (169 %) | (542 %) | (1311 %) |
EV / revenue | - | 13627.6x | 3.5x | 5.0x | 3.2x | 6.4x | 12.6x |
EV / EBITDA | -5371.1x | -3500.4x | -8.0x | -3.0x | - | - | - |
R&D budget | <1m | <1m | 153m | 157m | - | - | - |
R&D % of revenue | - | 438 % | 117 % | 242 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$23.0m | Series A | ||
N/A | $11.2m | Early VC | |
$19.8m | Grant | ||
$30.5m | Series B | ||
$142m | Series C | ||
$110m Valuation: $710m -9.4x EV/LTM EBITDA | Series D | ||
N/A | N/A | IPO | |
* | N/A | N/A | Post IPO Equity |
* | $50.0m | Post IPO Equity | |
Total Funding | $337m |
Recent News about Poseida Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.